Bruno Dubois

Bruno Dubois's AcademicInfluence.com Rankings

Bruno Dubois

Medical

#1055

World Rank

#1350

Historical Rank

Neurology

#99

World Rank

#150

Historical Rank

medical Degrees

Download Badge

Medical

Bruno Dubois's Degrees

PhD Neurology Stanford University

Why Is Bruno Dubois Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bruno Dubois's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) (6818)
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (2008) (4378)
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria (2007) (4004)
MDS clinical diagnostic criteria for Parkinson's disease (2015) (3560)
Diagnosis and management of dementia with Lewy bodies (2005) (3346)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria (2014) (2513)
Clinical diagnostic criteria for dementia associated with Parkinson's disease (2007) (2413)
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) (1996) (2382)
The FAB: A frontal assessment battery at bedside (2000) (1884)
Revising the definition of Alzheimer's disease: a new lexicon (2010) (1793)
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease (2014) (1634)
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization (2003) (1363)
Defeating Alzheimer's disease and other dementias: a priority for European science and society (2016) (1172)
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria (2016) (1163)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (1073)
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan (2007) (1068)
Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. (2006) (1050)
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers (2016) (1004)
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy (2012) (934)
Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force (2007) (918)
MDS research criteria for prodromal Parkinson's disease (2015) (897)
Cognitive deficits in Parkinson’s disease (1996) (801)
Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. (1999) (748)
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease (1983) (719)
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) (693)
Clinical spectrum of CADASIL: a study of 7 families (1995) (654)
Functions of the left superior frontal gyrus in humans: a lesion study. (2006) (651)
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline (2007) (639)
Direct Evidence for a Parietal-Frontal Pathway Subserving Spatial Awareness in Humans (2005) (620)
APOE and Alzheimer disease: a major gene with semi-dominant inheritance (2011) (528)
Cognitive control and brain resources in major depression: An fMRI study using the n-back task (2005) (479)
Amnestic MCI or prodromal Alzheimer's disease? (2004) (477)
The neural system that bridges reward and cognition in humans: An fMRI study (2002) (444)
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup (2011) (441)
Obsessive-compulsive and other behavioural changes with bilateral basal ganglia lesions. A neuropsychological, magnetic resonance imaging and positron tomography study. (1989) (427)
Support vector machine-based classification of Alzheimer’s disease from whole-brain anatomical MRI (2009) (426)
Coupled Temporal Memories in Parkinson's Disease: A Dopamine-Related Dysfunction (1998) (414)
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers (2017) (414)
Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging (2009) (397)
Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review (2015) (388)
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance (2012) (388)
Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease (2014) (384)
Executive functions and updating of the contents of working memory in unipolar depression. (2004) (366)
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease (2015) (365)
DLB and PDD boundary issues (2007) (351)
Consensus classification of posterior cortical atrophy (2017) (350)
Motivation, reward, and Parkinson’s disease: influence of dopatherapy (2002) (348)
Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. (2016) (333)
Implementation of subjective cognitive decline criteria in research studies (2017) (333)
Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. (1993) (323)
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease (2017) (322)
A phase II trial of tideglusib in Alzheimer's disease. (2015) (316)
Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. (1994) (314)
Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. (2008) (307)
Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease (1986) (306)
Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges (2015) (304)
TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration (2009) (301)
Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial (2012) (300)
Delusions and hallucinations are associated with worse outcome in Alzheimer disease. (2005) (296)
Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. (2015) (296)
Drug development in Alzheimer’s disease: the path to 2025 (2016) (295)
The role of dorsolateral prefrontal cortex in the preparation of forthcoming actions: an fMRI study. (2001) (281)
Congruent unilateral impairments for real and imagined hand movements (1995) (271)
Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. (1995) (271)
On the path to 2025: understanding the Alzheimer’s disease continuum (2017) (269)
Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus. (2008) (267)
Frontal assessment battery and differential diagnosis of frontotemporal dementia and Alzheimer disease. (2004) (262)
Relation of anosognosia to frontal lobe dysfunction in Alzheimer's disease. (1994) (253)
Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy (1991) (245)
Memory disorders in probable Alzheimer's disease: the role of hippocampal atrophy as shown with MRI. (1995) (244)
Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. (2010) (244)
Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology (1994) (234)
Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. (1998) (228)
Amnestic syndrome of the medial temporal type identifies prodromal AD (2007) (227)
Motor signs during the course of Alzheimer disease (2004) (216)
Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference. (2015) (215)
The neuropsychological pattern of corticobasal degeneration (1995) (213)
Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom (2008) (212)
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. (2002) (204)
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group (2021) (204)
Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. (1990) (202)
Brain networks of spatial awareness: evidence from diffusion tensor imaging tractography (2007) (201)
Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? (1989) (197)
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease (2011) (191)
Motor signs predict poor outcomes in Alzheimer disease (2005) (189)
Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis (2008) (184)
Disconnecting force from money: effects of basal ganglia damage on incentive motivation. (2008) (181)
Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty (2014) (180)
A Selective Impairment of Hand Posture for Object Utilization in Apraxia (1995) (177)
Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease A one-year follow-up study (2006) (175)
The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative (2014) (174)
Pure psychic akinesia with bilateral lesions of basal ganglia. (1984) (171)
Somatostatin and dementia in Parkinson's disease (1983) (170)
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. (2015) (169)
Progranulin null mutations in both sporadic and familial frontotemporal dementia (2007) (169)
Riluzole in Huntington's disease: a 3‐year, randomized controlled study (2007) (169)
Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment (1989) (167)
Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. (1993) (167)
Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group (2018) (165)
Anatomically constrained region deformation for the automated segmentation of the hippocampus and the amygdala: Method and validation on controls and patients with Alzheimer’s disease (2007) (164)
CONFABULATION, EXECUTIVE FUNCTIONS, AND SOURCE MEMORY IN ALZHEIMER'S DISEASE (1999) (164)
Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. (2006) (164)
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias (2020) (163)
Selective Impairments in Managerial Knowledge Following Pre-Frontal Cortex Damage (1995) (163)
Sensitivity to semantic cuing: an index of episodic memory dysfunction in early Alzheimer disease. (1999) (163)
Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease. (1988) (162)
Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study (2012) (162)
Report of the task force on designing clinical trials in early (predementia) AD (2010) (162)
Neural correlates of cognitive impairment in posterior cortical atrophy. (2011) (161)
Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2 (2011) (159)
Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson's disease and progressive supranuclear palsy. (1995) (158)
Dementia with Lewy bodies (2004) (158)
Cholinergic‐dependent cognitive deficits in Parkinson's disease (1987) (156)
A frontal assessment battery at bedside (2000) (154)
Deficit of verb generation in nondemented patients with Parkinson's disease (2003) (149)
The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study. (2010) (148)
Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study (2018) (146)
Disruptive behavior as a predictor in Alzheimer disease. (2007) (144)
Impaired simultaneous cognitive task performance in Parkinson's disease (1994) (143)
Are cognitive changes the first symptoms of Huntington’s disease? A study of gene carriers (1998) (143)
Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. (1997) (143)
Confusion, dementia and anticholinergics in Parkinson's disease. (1982) (140)
Social Cognition and Emotional Assessment differentiates frontotemporal dementia from depression (2012) (137)
Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force (2013) (137)
Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. (2013) (137)
Clinicometabolic dissociation of cognitive functions and social behavior in frontal lobe lesions (1998) (136)
An Ecological Approach to Planning Dysfunction: Script Execution (2000) (134)
Encoding of Sequence and Boundaries of Scripts Following Prefrontal Lesions (1996) (134)
Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases (1994) (133)
Delayed response tasks in basal ganglia lesions in man: Further evidence for a striato-frontal cooperation in behavioural adaptation (1996) (132)
Cholinergic deficiency and frontal dysfunction in Parkinson's disease (1990) (132)
Preserved Adjustment but Impaired Awareness in a Sensory-Motor Conflict following Prefrontal Lesions (2001) (132)
The SEA (Social cognition and Emotional Assessment): a clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration. (2012) (129)
A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch (2007) (126)
Distinct prefrontal activations in processing sequence at the sentence and script level: An fMRI study (1999) (126)
Explicit Memory, Procedural Learning and Lexical Priming in Alzheimer's Disease (1994) (123)
CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study (2015) (119)
Harmonized diagnostic criteria for Alzheimer's disease: recommendations (2014) (118)
Similar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease. (2011) (117)
Age‐induced cognitive disturbances in Parkinson's disease (1990) (116)
[Mini-Mental State Examination:a useful method for the evaluation of the cognitive status of patients by the clinician. Consensual French version]. (1999) (116)
DTI-MR tractography of white matter damage in stroke patients with neglect (2011) (115)
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease (2021) (113)
Progressive supranuclear palsy: anatomoclinical and biochemical considerations. (1987) (113)
Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson’s disease? (2005) (112)
EFNS task force: the use of neuroimaging in the diagnosis of dementia (2012) (111)
“Applause sign” helps to discriminate PSP from FTD and PD (2005) (111)
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised (2021) (110)
CSF tau markers are correlated with hippocampal volume in Alzheimer's disease (2012) (109)
Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. (2014) (108)
Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia (2018) (107)
Delayed response tasks and prefrontal lesions in man—Evidence for self generated patterns of behaviour with poor environmental modulation (1993) (107)
Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes? (2007) (106)
Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. (2018) (105)
Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease (2009) (105)
A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling (2017) (103)
Poor creativity in frontotemporal dementia: A window into the neural bases of the creative mind (2010) (103)
The functional architecture of the left posterior and lateral prefrontal cortex in humans. (2007) (102)
Association between the extended tau haplotype and frontotemporal dementia. (2002) (98)
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease (2019) (98)
FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. (2010) (98)
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease (2019) (98)
Diagnosis and management of Parkinson's disease dementia (2008) (97)
Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis (2002) (96)
Early Cognitive, Structural, and Microstructural Changes in Presymptomatic C9orf72 Carriers Younger Than 40 Years (2018) (96)
What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons (2019) (94)
Corticobasal degeneration: Decreased and asymmetrical glucose consumption as studied with PET (1992) (93)
Two Distinct Amnesic Profiles in Behavioral Variant Frontotemporal Dementia (2014) (91)
Is impaired memory for spatial location in Parkinson's disease domain specific or dependent on ‘strategic’ processes? (1998) (91)
Depressive Symptoms in Alzheimer's Disease: Natural Course and Temporal Relation to Function and Cognitive Status (2005) (91)
PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. (2016) (90)
Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial (2015) (90)
Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy (2001) (89)
Importance of lack of interest in patients with mild cognitive impairment. (2008) (88)
C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. (2013) (88)
EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. (2019) (87)
Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease (2016) (86)
Dopamine and cognitive function (2003) (85)
A multidisciplinary study of patients with early-onset PD with and without parkin mutations (2009) (84)
Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia? (2013) (84)
Validity of the Free and Cued Selective Reminding Test in predicting dementia (2010) (83)
Perception of self-generated action in schizophrenia (2002) (82)
Distinct striatal regions support movement selection, preparation and execution (2004) (82)
Early detection of Alzheimer's disease: new diagnostic criteria (2009) (80)
Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1–42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40 (2018) (80)
Homozygous TREM2 mutation in a family with atypical frontotemporal dementia (2014) (80)
Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease (2018) (80)
Detection of volume loss in hippocampal layers in Alzheimer's disease using 7 T MRI: A feasibility study (2014) (79)
VBM anticipates the rate of progression of Alzheimer disease (2008) (79)
'Prodromal Alzheimer's disease': a more useful concept than mild cognitive impairment? (2000) (79)
Frontal Assessment Battery is a marker of dorsolateral and medial frontal functions: A SPECT study in frontotemporal dementia (2008) (78)
Brain glutamate decarboxylase in Parkinson's disease with particular reference to a premortem severity index. (1985) (78)
Striatal dopamine D2 receptors in tardive dyskinesia: PET study. (1989) (78)
Early diagnosis of Alzheimer’s disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts (2020) (78)
Memory for spatial location is affected in Parkinson's disease (1996) (77)
Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment (2011) (76)
Testing the model of caudo-rostral organization of cognitive control in the human with frontal lesions (2014) (76)
Subtle cognitive impairment but no dementia in patients with spastin mutations. (2003) (75)
Effects of internal clock and memory disorders on duration reproductions and duration productions in patients with Parkinson’s disease (2005) (75)
Neuropsychological Performance in Mild Cognitive Impairment with and without Apathy (2006) (75)
Cognitive and behavioral changes in patients with focal lesions of the basal ganglia. (1995) (75)
Precision pharmacology for Alzheimer's disease. (2018) (74)
TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts (2015) (74)
Biomarkers in Sporadic and Familial Alzheimer's Disease. (2015) (74)
Temporal Order Memory Assessed during Spatiotemporal Navigation As a Behavioral Cognitive Marker for Differential Alzheimer's Disease Diagnosis (2012) (74)
Biochemical substrates of mental disturbances in Parkinson's disease. (1984) (73)
Auto‐Activation deficit: A basal ganglia related syndrome (2001) (73)
Testing cognition may contribute to the diagnosis of movement disorders (1996) (73)
International Work Group criteria for the diagnosis of Alzheimer disease. (2013) (72)
Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future (2015) (71)
Acute and Long-Term Administration of Anticholinergics in Parkinson's Disease: Specific Effects on the Subcortico-Frontal Syndrome (1999) (71)
Clinical and research diagnostic criteria for Alzheimer's disease. (2012) (70)
Sensitivity and specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal dementia (2013) (70)
EFFICACY AND TOLERABILITY OF RIVASTIGMINE IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER TYPE (1998) (69)
The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group (2017) (69)
Lesions of basal ganglia due to disulfiram neurotoxicity. (1992) (69)
Forced collectionism after orbitofrontal damage. (2002) (69)
Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints (2018) (69)
Loss of brain inter-frequency hubs in Alzheimer's disease (2016) (68)
The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? (1990) (67)
Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease (2017) (67)
Social Cognition and Emotional Assessment (SEA) is a Marker of Medial and Orbital Frontal Functions: A Voxel-Based Morphometry Study in Behavioral Variant of Frontotemporal Degeneration (2012) (67)
Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies (2019) (66)
Procedural learning and striatofrontal dysfunction in Parkinson's disease (2002) (65)
Memory for spatial location in ‘de novo’ parkinsonian patients (1997) (65)
Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. (2000) (65)
Specificity of Memory Deficits after Right or Left Temporal Lobectomy (1999) (64)
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. (2014) (63)
Brain networks in posterior cortical atrophy: A single case tractography study and literature review (2012) (62)
Visual neglect in posterior cortical atrophy (2010) (61)
Common brain networks for distinct deficits in visual neglect. A combined structural and tractography MRI approach (2017) (61)
Apolipoprotein E ϵ4 Allele and Familial Aggregation of Alzheimer Disease (1998) (61)
Does ageing aggravate parkinsonian disability? (1991) (61)
Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept (2017) (60)
Cognitive function, insulin‐dependent diabetes and hypoglycaemia (1992) (59)
Free and Cued Selective Reminding Test – accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: A large-scale biomarker-characterized monocenter cohort study (ClinAD) (2017) (58)
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, genetic homogeneity, and mapping of the locus within a 2-cM interval. (1996) (57)
Frontotemporal dementia: Pathology of gait? (2010) (57)
Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study (2006) (57)
How cognitive performance‐induced stress can influence right VLPFC activation: An fMRI study in healthy subjects and in patients with social phobia (2012) (56)
The prefrontal cortex and conscious monitoring of action An experimental study (2003) (55)
Is the HM story only a ‘remote memory’? Some facts about hippocampus and memory in humans (2001) (55)
TDP-43 M311V mutation in familial amyotrophic lateral sclerosis (2009) (55)
Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. (1997) (55)
Working memory in Parkinson's disease patients: clinical features and response to levodopa. (2008) (54)
Measuring cognitive change in subjects with prodromal Alzheimer's disease (2013) (54)
Change in body mass index before and after Alzheimer's disease onset. (2014) (53)
The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study. (2013) (53)
Frontal lobe neurology and the creative mind (2014) (53)
Alzheimer's Disease Including Focal Presentations (2019) (53)
Rostro-caudal Architecture of the Frontal Lobes in Humans (2016) (52)
Accumulation of flotillin‐1 in tangle‐bearing neurones of Alzheimer's disease (2003) (52)
Social Cognition Deficits: The Key to Discriminate Behavioral Variant Frontotemporal Dementia from Alzheimer's Disease Regardless of Amnesia? (2015) (52)
Recommendations for ICT use in Alzheimer’s disease assessment: Monaco CTAD expert meeting (2013) (52)
Screening for Alzheimer’s Disease with the Short Cognitive Evaluation Battery (2003) (51)
How Preserved is Emotion Recognition in Alzheimer Disease Compared With Behavioral Variant Frontotemporal Dementia? (2014) (51)
Clinical validation of movement disorder society–recommended diagnostic criteria for Parkinson's disease with dementia (2012) (50)
The occurrence of mutations in FUS in a Belgian cohort of patients with familial ALS (2010) (50)
Early Detection of Mild Cognitive Impairment (MCI) in Primary Care (2020) (50)
Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease (2017) (49)
Parkinson's disease dementia can be easily detected in routine clinical practice (2010) (49)
Understanding facial emotion perception in Parkinson's disease: The role of configural processing (2011) (49)
Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework (2017) (48)
Mirror reading in Alzheimer's disease: normal skill learning and acquisition of item-specific information. (1993) (47)
A large pedigree with early-onset Alzheimer's disease (1995) (47)
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease (2012) (47)
Neural correlates of the mini-SEA (Social cognition and Emotional Assessment) in behavioral variant frontotemporal dementia (2014) (47)
Spatio-Temporal Working Memory and Frontal Lesions in Man * * A subset of this data was presented at the XXVI International Congress of Psychology, Montreal, August 1996. (1998) (47)
Specific cerebral networks for maintenance and response organization within working memory as evidenced by the 'double delay/double response' paradigm. (2005) (46)
Severe traumatic brain injury, frontal lesions, and social aspects of language use: a study of French-speaking adults. (2011) (46)
Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study (2018) (46)
The Brain Network of Naming: A Lesson from Primary Progressive Aphasia (2016) (46)
A novel approach to clinical–radiological correlations: Anatomo-Clinical Overlapping Maps (AnaCOM): Method and validation (2007) (46)
Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. (1998) (46)
Myosin storage myopathy: Slow skeletal myosin (MYH7) mutation in two isolated cases (2005) (45)
Confabulation in Alzheimer's disease: poor encoding and retrieval of over-learned information. (2009) (45)
Abolishing the 1‐year rule: How much evidence will be enough? (2016) (45)
Defining the spectrum of frontotemporal dementias associated with TARDBP mutations (2016) (45)
The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology (2017) (45)
Direct current stimulation over the anterior temporal areas boosts semantic processing in primary progressive aphasia (2016) (45)
An Effect of Dopamine Depletion on Decision-making: The Temporal Coupling of Deliberation and Execution (2005) (44)
DTI and Structural MRI Classification in Alzheimer’s Disease (2012) (43)
Consensus statement on dementia of Alzheimer type in the severe stage. (2005) (43)
Parkinson's disease is a neuropsychiatric disorder. (2003) (43)
Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers (2018) (43)
Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers (2018) (43)
Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease (2017) (42)
Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds (2018) (42)
Determinants of theory of mind performance in Alzheimer's disease: A data-mining study (2017) (41)
Are Frontal Cognitive and Atrophy Patterns Different in PSP and bvFTD? A Comparative Neuropsychological and VBM Study (2013) (41)
A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). (2015) (40)
Deficit in Evaluating Pre-Determinated Sequences of Script Events in Patients with Parkinson's Disease (1998) (39)
Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease. (2017) (39)
A Multitracer Dopaminergic PET Study of Young-Onset Parkinsonian Patients With and Without Parkin Gene Mutations (2009) (39)
[Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation]. (1985) (39)
Paths to Alzheimer’s disease prevention: From modifiable risk factors to biomarker enrichment strategies (2015) (39)
Is the Saitohin gene involved in neurodegenerative diseases? (2002) (39)
Ropinirole without levodopa in Parkinson's disease (1990) (38)
Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease (2019) (38)
At which steps of spatial working memory processing do striatofrontal circuits intervene in humans? (1998) (38)
Intrusions in story recall: When over-learned information interferes with episodic memory recall. Evidence from Alzheimer's disease (2008) (38)
The Emergence of a New Conceptual Framework for Alzheimer’s Disease (2017) (37)
In two minds: executive functioning versus theory of mind in behavioural variant frontotemporal dementia (2015) (37)
Social cognition in Alzheimer's disease: A separate construct contributing to dependence (2014) (37)
Meta-analysis of genetic association with diagnosed Alzheimer’s disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing (2018) (36)
Lateral Temporal Lobe: An Early Imaging Marker of the Presymptomatic GRN Disease? (2015) (36)
Research goals in progressive supranuclear palsy (2000) (35)
Neuropsychological predictors of dependency in patients with Alzheimer disease (2005) (35)
Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) supported by Emerging Digital Technologies (2019) (35)
Biomarker-guided clustering of Alzheimer's disease clinical syndromes (2019) (35)
Functional Connectivity of Ventral and Dorsal Visual Streams in Posterior Cortical Atrophy. (2016) (35)
Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease. (2016) (34)
Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. (2017) (34)
General practice-based intervention for suspecting and detecting dementia in France (2008) (34)
Do cognitive changes of Parkinson's disease result from dopamine depletion? (1995) (33)
Sulcal morphology as a new imaging marker for the diagnosis of early onset Alzheimer's disease (2015) (33)
Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort (2017) (33)
Plasma DYRK1A as a novel risk factor for Alzheimer's disease (2014) (33)
Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease‐modifying therapies (2020) (33)
Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. (2015) (33)
How Patients with Parkinson's Disease Retrieve and Manage Cognitive Event Knowledge (2000) (33)
Is PD‐MCI a useful concept? (2007) (32)
Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis (2020) (32)
Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers (2019) (32)
Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting (2019) (32)
Discounting of future rewards in behavioural variant frontotemporal dementia and Alzheimer's disease. (2015) (32)
A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations. (2009) (31)
CATI: A Large Distributed Infrastructure for the Neuroimaging of Cohorts (2016) (31)
Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease. (2016) (31)
The influence of semantic and perceptual encoding on recognition memory in Alzheimer’s disease (1998) (31)
Why do patients with neurodegenerative frontal syndrome fail to answer: 'In what way are an orange and a banana alike?'. (2015) (30)
Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments (2014) (30)
Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel (2021) (30)
Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: The INSIGHT-preAD study (2019) (29)
Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease. (1998) (29)
Mechanical stress related to brain atrophy in Alzheimer's disease (2016) (29)
[Cognitive functions and the basal ganglia: the model of Parkinson disease]. (1994) (28)
World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care (2015) (28)
Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease (2019) (28)
Metabolic correlates of behavioral and affective disturbances in frontal lobe pathologies (2003) (28)
Structural, Microstructural, and Metabolic Alterations in Primary Progressive Aphasia Variants (2018) (28)
Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults (2018) (28)
Relationship between attentional performance and corpus callosum morphometry in patients with Alzheimer’s disease (2002) (28)
Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease (2017) (28)
Cholinergic-dependent cognitive deficits in Parkinsonʼs disease (1988) (28)
Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada (2016) (28)
Semantic and nonfluent aphasic variants, secondarily associated with amyotrophic lateral sclerosis, are predominant frontotemporal lobar degeneration phenotypes in TBK1 carriers (2015) (27)
Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort. (2015) (27)
Distinct patterns of antiamyloid-β antibodies in typical and atypical Alzheimer disease. (2012) (27)
Visuospatial deficits in posterior cortical atrophy: structural and functional correlates (2012) (27)
Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. (2015) (27)
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (26)
CHMP2B mutations are rare in French families with frontotemporal lobar degeneration (2010) (26)
Alzheimer disease: from biomarkers to diagnosis. (2013) (26)
Effectiveness of Florbetapir PET Imaging in Changing Patient Management (2017) (26)
Prevention of progression to dementia in the elderly: Rationale and proposal for a health-promoting memory consultation (an IANA task force) (2008) (25)
Logopenic progressive aphasia beyond Alzheimer's—an evolution towards dementia with Lewy bodies (2012) (25)
Mechanical Stress as the Common Denominator between Chronic Inflammation, Cancer, and Alzheimer’s Disease (2015) (25)
Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid-β Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. (2019) (24)
Frontal presentation of Alzheimer's disease: a series of patients with biological evidence by CSF biomarkers (2013) (24)
No founder effect in three novel Alzheimer's disease families with APP 717 Val-->Ile mutation. Clerget-darpoux. French Alzheimer's Disease Study Group. (1996) (24)
Online information and support for carers of people with young‐onset dementia: A multi‐site randomised controlled pilot study (2019) (24)
Pure Topographical Disorientation Following a Right Forceps Major of the Splenium Lesion: A Case Study (2007) (24)
RHAPSODY – Internet-based support for caregivers of people with young onset dementia: program design and methods of a pilot study (2016) (24)
Relationships between objectives sleep parameters and brain amyloid load in subjects at risk to Alzheimer's disease: the INSIGHT-preAD Study. (2019) (24)
Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study (2019) (24)
Fully automatic hippocampus segmentation discriminates between early Alzheimer’s disease and normal aging (2008) (23)
Distinct brain perfusion pattern associated with CSF biomarkers profile in primary progressive aphasia (2012) (23)
Use of haplotype information to test involvement of the LRP gene in Alzheimer's disease in the French population (2001) (23)
Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease (2010) (22)
Identification of Atrophy Patterns in Alzheimer's Disease Based on SVM Feature Selection and Anatomical Parcellation (2008) (22)
Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers (2018) (22)
Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study (2020) (22)
Neural correlates of primary and reflective consciousness of spatial orienting (2008) (22)
Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study (2019) (22)
[Validation of the French language version of the Parkinson's Disease Questionnaire - PDQ-39]. (2002) (22)
Semantic loss marks early Alzheimer's disease‐related neurodegeneration in older adults without dementia (2020) (21)
Visuospatial deficits and hemispheric perfusion asymmetries in posterior cortical atrophy (2013) (21)
White matter lesions in FTLD: distinct phenotypes characterize GRN and C9ORF72 mutations (2016) (21)
Cognitive dissonance resolution depends on episodic memory (2017) (21)
Can we still dream when the mind is blank? Sleep and dream mentations in auto-activation deficit. (2013) (21)
Results from a Phase II Study to Assess the Clinical and Immunological Activity of AFFITOPE® AD02 in Patients with Early Alzheimer's Disease. (2015) (21)
Mechanical stress models of Alzheimer's disease pathology (2016) (21)
[Alzheimer's disease: a public health problem: yes, but a priority?]. (2002) (21)
Parkinson's Disease and Dementia (1986) (21)
Posterior cortical atrophy as an extreme phenotype of GRN mutations. (2015) (20)
Efficacy and safety of gantenerumab in prodromal Alzheimer’s disease: Results from scarlet road—a global, multicenter trial (2015) (20)
Similar subcortical pattern of cognitive impairment in AIDS patients with and without dementia (2000) (20)
Similar or Different? The Role of the Ventrolateral Prefrontal Cortex in Similarity Detection (2012) (20)
A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine (1995) (20)
New diagnostic criteria for (2012) (19)
Clinical investigations in primary care. (2009) (19)
Revised research diagnostic criteria for Alzheimer's disease (2008) (19)
BRAIN SPECT PERFUSION OF FRONTOTEMPORAL DEMENTIA ASSOCIATED WITH MOTOR NEURON DISEASE (2007) (19)
Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. (2016) (19)
MOTONEURON DISEASE AS MANIFESTATION OF LUPIN SEED TOXICITY (1988) (18)
Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment (2017) (18)
Early detection of patients in the pre demented stage of Alzheimer’s disease: The Pre-Al study (2009) (18)
Tau levels do not influence human ALS or motor neuron degeneration in the SOD1G93A mouse (2010) (18)
Modifications of the endosomal compartment in peripheral blood mononuclear cells and fibroblasts from Alzheimer's disease patients (2015) (18)
Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study (2020) (18)
Mechanical stress increases brain amyloid β, tau, and α-synuclein concentrations in wild-type mice (2018) (18)
Biological markers of Alzheimer's disease. (2014) (18)
Cognitive and behavioural inhibition deficits in neurodegenerative dementias (2020) (18)
Low Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer’s Disease (2017) (17)
Judgments about moral responsibility and determinism in patients with behavioural variant of frontotemporal dementia: Still compatibilists (2012) (17)
The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries (2019) (17)
Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment. (2016) (17)
No effect of the α1-antichymotrypsin A allele in Alzheimer’s disease (1997) (17)
Disrupted core-periphery structure of multimodal brain networks in Alzheimer’s disease (2018) (17)
Biomarker counseling, disclosure of diagnosis and follow‐up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey (2020) (17)
A risk for early-onset Alzheimer's disease associated with the APBB1 gene (FE65) intron 13 polymorphism (2003) (16)
So Close Yet So Far: Executive Contribution to Memory Processing in Behavioral Variant Frontotemporal Dementia. (2016) (16)
Neural correlates of episodic memory in the Memento cohort (2018) (16)
Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD (2019) (16)
AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials (2011) (16)
Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints (2017) (16)
Memory and executive processes in corticobasal degeneration. (2000) (16)
In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease (2020) (16)
Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD (2019) (16)
[Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice]. (2003) (16)
[Mild Cognitive Impairment or pre-demential Alzheimer's disease?]. (2002) (15)
Disappearance of parkinsonian signs after spontaneous vascular 'thalamotomy'. (1986) (15)
Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience (2020) (15)
α2‐Macroglobulin gene and Alzheimer's disease: Confirmation of association by haplotypes analyses (2000) (15)
Neuroimaging in dementias (2012) (15)
Simultanagnosia in a patient with right brain lesions (2000) (15)
Influence of early maladaptive schemas, depression, and anxiety on the intensity of self-reported cognitive complaint in older adults with subjective cognitive decline (2017) (15)
The utility of the new research diagnostic criteria for Alzheimer's disease (2012) (14)
Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe (2021) (14)
Group and individual cognitive therapies in Alzheimer ’ s disease : the ETNA 3 randomized trial (2016) (14)
Does amnesia specifically predict Alzheimer’s pathology? A neuropathological study (2020) (14)
[Validity of the five-word screening test for Alzheimer's disease in a population based study]. (2005) (14)
Multimorbidity Is Associated with Preclinical Alzheimer’s Disease Neuroimaging Biomarkers (2018) (13)
No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints (2017) (13)
Comparison of patient and caregiver reports of patient activity participation and its relationship to mental health in patients with Alzheimer's disease. (2009) (13)
Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. (1997) (13)
Relapsing-remitting behavioural variant of frontotemporal dementia in a bipolar patient. (2012) (13)
Cognitive inhibition impairments in presymptomatic C9orf72 carriers (2020) (13)
Should the Social Cognition and Emotional Assessment replace standard neuropsychological tests for frontotemporal dementia? (2012) (13)
How to Study Frontal Lobe Functions in Humans (1994) (13)
Influence of Lewy Pathology on Alzheimer’s Disease Phenotype: A Retrospective Clinico-Pathological Study (2018) (13)
European Academy of Neurology/European Alzheimer’s Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment (2020) (12)
Similar amyloid- b burden in posterior cortical atrophy and Alzheimer’s disease (2011) (12)
[Consensus statement of an interdisciplinary group of French experts on modalities of diagnosis and medical treatment of Alzheimer's disease at a treatable stage]. (1998) (12)
How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years (2019) (12)
[Loss of psychic self-activation and stereotyped mental activity caused by a frontal lesion. Relation of the obsessive-compulsive disorder]. (1988) (12)
Education and training of European neurologists in dementia (2007) (12)
Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761. (2015) (12)
France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer's Disease. (2018) (12)
Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales. (2015) (12)
Re-aligning scientific and lay narratives of Alzheimer's disease (2019) (11)
Clinical relevance of brain atrophy subtypes categorization in memory clinics (2020) (11)
Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD (2020) (11)
Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease. (1993) (11)
Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease (2015) (11)
A mosquito bites and a butterfly flies: A specific response type of frontal patients in a similarity task (2018) (11)
Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias (2018) (11)
Fronto-temporal lobar degeneration: neuropathology in 60 cases (2011) (11)
Exploration Deficits Under Ecological Conditions as a Marker of Apathy in Frontotemporal Dementia (2019) (11)
French consensus procedure for assessing cognitive function in Parkinson's disease. (2016) (11)
Language boosting by transcranial stimulation in progressive supranuclear palsy (2019) (11)
For a Cognitive Model of Subjective Memory Awareness. (2015) (11)
Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis (2021) (11)
Analysing time to event data in dementia prevention trials: The example of the guidage study of EGB761® (2015) (11)
Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers (2020) (10)
A machine learning approach to screen for preclinical Alzheimer's disease (2021) (10)
Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study (2016) (10)
Accuracy of MRI Classification Algorithms in a Tertiary Memory Center Clinical Routine Cohort. (2020) (10)
Behavioral variant frontotemporal dementia patients do not succumb to the Allais paradox (2014) (10)
Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease (2019) (10)
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease (2015) (10)
ACCURACY OF MRI CLASSIFICATION ALGORITHMS IN A TERTIARY MEMORY CENTER CLINICAL ROUTINE COHORT (2017) (10)
Executive dysfunction and neuropsychological testing. (2008) (10)
[Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease]. (2007) (10)
No replication of the association between the Nicastrin gene and familial early-onset Alzheimer's disease (2003) (9)
Effect of six months of treatment with V0191 in patients with suspected prodromal Alzheimer's disease. (2012) (9)
[Affective disorders due to the loss of mental self-activation. Comparison with athymhormia]. (1998) (9)
Which Episodic Memory Performance is Associated with Alzheimer's Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD). (2019) (9)
Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice (2018) (9)
Dementia pugilistica: a severe tribute to a career. (2015) (8)
Efficacy of serious exergames in improving neuropsychiatric symptoms in neurocognitive disorders: Results of the X‐TORP cluster randomized trial (2021) (8)
Characteristics of familial aggregation in early-onset Alzheimer's disease: evidence of subgroups. (1995) (8)
Testing the therapeutic effects of transcranial direct current stimulation (tDCS) in semantic dementia: a double blind, sham controlled, randomized clinical trial (2019) (8)
Balneotherapy, prevention of cognitive decline and care the Alzheimer patient and his family: Outcome of a multidisciplinary workgroup (2009) (8)
A Reliable and Rapid Language Tool for the Diagnosis, Classification, and Follow-Up of Primary Progressive Aphasia Variants (2021) (8)
Radiological classification of dementia from anatomical MRI assisted by machine learning-derived maps. (2020) (8)
Cognition, behavior and the frontal lobes (2004) (7)
The role of semantic memory in prospective memory and episodic future thinking: new insights from a case of semantic dementia (2021) (7)
Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET) (2021) (7)
Moral Emotions in Frontotemporal Dementia. (2019) (7)
A phase II randomized, double-blind, parallel group, 26-week study of GSK-3 inhibitor tideglusib in Alzheimer's disease (ARGO trial) (2013) (7)
Simultaneous quantification of tau and α-synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls. (2019) (7)
RADIOLOGICAL CLASSIFICATION OF DEMENTIA FROM ANATOMICAL MRI ASSISTED BY MACHINE LEARNING-DERIVED MAPS (2019) (7)
A New Window on Child Prefrontal Functions: Inhibition of a Non-Strategic Alternation-Pointing Scheme (2001) (7)
The cognitive syndrome of progressive supranuclear palsy. (1996) (7)
Interest of the new criteria for drug trials in AD (2009) (7)
Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Commentary (1998) (6)
Addressing non-motor impairments in Parkinson's disease: The new version of the UPDRS (2005) (6)
Medical Clinics of North America. Early diagnosis and intervention in predementia Alzheimer's disease. Preface. (2013) (6)
Cognitive deficits in non-Alzheimer's degenerative diseases. (1996) (6)
Severity and Specificity of Cognitive Impairment in Alzheimer's, Huntington's, and Parkinson's Diseases and Progressive Supranuclear Palsy (1991) (6)
[Fronto-temporal dementia: a clinical approach]. (1999) (6)
["Boxer's dementia" without motor signs]. (1999) (6)
STUDY DESIGN AND CHARACTERISTICS OF TWO PHASE II PROOF-OF-CONCEPT CLINICAL TRIALS OF THE PDE9 INHIBITOR BI 409306 IN EARLY ALZHEIMER'S DISEASE (2016) (6)
Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing (2014) (6)
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease (2018) (6)
Primary Progressive Aphasia Associated With GRN Mutations (2021) (6)
[A guide to diagnosis of Alzheimer's disease]. (2005) (5)
Investigating the association between cancer and the risk of dementia: Results from the Memento cohort (2021) (5)
[Beneficial effect of a cognitive behavioral and multidisciplinary program in Alzheimer Disease on spouse caregiver anxiety: French study ELMMA]. (2011) (5)
Altered age‐linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT‐preAD study) with high brain amyloid load (2020) (5)
Prediction of Amyloidosis from Neuropsychological and MRI Data for Cost Effective Inclusion of Pre-symptomatic Subjects in Clinical Trials (2017) (5)
Research goals in progressive supranuclear palsy. First International Brainstorming Conference on PSP. (2000) (5)
EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. (2014) (5)
Doescognitive impairment inParkinson's disease result fromnon-dopaminergic lesions? (1989) (5)
Dementia in Patients with Parkinson’s Disease: Review of Biochemical Data (1985) (5)
The missense p.Trp7Arg mutation in GRN gene leads to progranulin haploinsufficiency (2020) (5)
Plasma β‐secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD (2021) (5)
[The Goblets test: Norms in the elderly population and properties in the detection of cognitive impairment in elderly individuals selected from the general population]. (2013) (5)
A randomized, controlled, multicenter, international study of the impact of florbetapir (18F) PET amyloid imaging on patient management and outcome (2015) (4)
[Semantic dementia associated with amyotrophic lateral sclerosis]. (2009) (4)
Association of brain network dynamics with plasma biomarkers in subjective memory complainers (2019) (4)
Efficacy, Safety and Biomarker Data from SCarlet RoAD—a Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD (2016) (4)
Gantenerumab in‐depth outcomes: Results of the DIAN‐TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD (2020) (4)
CSF and amyloid pet biomarker data from scarlet road - a global Phase 3 study of gantenerumab in patients with prodromal AD (2016) (4)
Efficacy, Safety and Biomarker Data from SCarlet RoAD - A Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD (S1.002) (2016) (4)
“A mosquito bites and a butterfly flies": a specific response type of frontal patients in a similarity task (2017) (4)
Plasma DYRK 1 A as a novel risk factor for Alzheimer ’ s disease (2018) (4)
Additional results from a phase ii study to assess the clinical and immunological activity, safety, and tolerability of affitope® ad02 in patients with early Alzheimer’s disease (AD) (2015) (4)
International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration (2001) (4)
Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab (2020) (4)
Behavioral changes in patients with focal lesions of the basal ganglia. (2005) (4)
Effects of donepezil on structural MRI and clinical markers in patients with amnestic mild cognitive impairment: A randomized, placebo-controlled trial (2009) (4)
Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease (2018) (4)
LOW COGNITIVE AWARENESS, BUT NOT COMPLAINT, IS A GOOD MARKER OF PRECLINICAL ALZHEIMER'S DISEASE (2017) (4)
Allelic association at the D14S43 locus in early onset Alzheimer's disease. French Alzheimer's Disease Collaborative Study Group. (1995) (4)
A mental lexicon without semantics (2012) (4)
[Phenotype of familial forms of early-onset Alzheimer's disease linked to chromosome 14. Clinical and neuropsychological characteristics of a large group]. (1995) (3)
Natural history of Alzheimer’s disease and other dementing illnesses (2002) (3)
Relationship between Discrimination Tasks of the Cantab and the Corpus Callosum Morphology in Alzheimer's Disease (2001) (3)
New version of the UPDRS: Development methods and working document for field testing (2005) (3)
[Consensus statement on severe dementia]. (2005) (3)
Added Value of the Neuropsychological Evaluation for Diagnosis and Research of Atypical Parkinsonian Disorders (2005) (3)
Competitive segmentation of the hippocampus and the amygdala from MRI data: validation on young healthy controls and Alzheimer's disease patients (2006) (3)
SVM classification of patients with Alzheimer's disease and mild cognitive impairment using hippocampal shape features (2009) (3)
[Towards a national strategy on the diagnosis of neurocognitive disorders. A shared approach among the French National College of General Practitioners and specialists of neurocognitive disorders]. (2017) (3)
Deterioration of dopaminergic pathways and alterations in cognition and motor functions (1992) (3)
Biomarkers for the early stages of clinical development in Alzheimer's disease. (2010) (3)
Combined assessment of DYRK 1 A , BDNF and homocysteine levels as diagnostic marker for Alzheimer ’ s disease (2018) (3)
[Viewpoint on the methodology of drug trials affecting cognition of elderly patients]. (1994) (3)
Improved Accuracy of the Diagnosis of Early Alzheimer’s Disease Using Combined Measures of Hippocampal Volume and Sulcal Morphology (P4.016) (2014) (3)
Parietal Involvement in the Semantic Variant of Primary Progressive Aphasia with Alzheimer's Disease Cerebrospinal Fluid Profile. (2018) (3)
Loss of inter-frequency brain hubs in Alzheimer's disease (2016) (3)
SCREENING FOR AD: WHY AND HOW? (2014) (3)
Natural decline and prognostic factors (2006) (3)
Are PSP patients included in clinical trials representative of the general PSP population? (2019) (3)
Genetic risk factors for posterior cortical atrophy (2015) (3)
Neuropsychological methods in mild cognitive impairment (2004) (3)
[A new definition for Alzheimer's disease]. (2013) (3)
[Converging opinions of a multidisciplinary group of French experts on diagnostic and therapeutic modalities for Alzheimer type dementia]. (2000) (3)
Review Article Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease (2014) (2)
Differential caudate-prefrontal activation during the initial and late stages of mirror reading learning: A FMRI study (2001) (2)
The White Matter Module-Hub Network of Semantics Revealed by Semantic Dementia (2020) (2)
[Alzheimer's disease: therapeutic perspectives]. (2008) (2)
PREVENTION OF PROGRESSION TO DEMENTIA IN THE ELDERLY: RATIONALE AND PROPOSAL FOR A HEALTH-PROMOTING MEMORY CONSULTATION (TASK FORCE MEMBERS) (2008) (2)
Anatomo-clinical overlapping maps (AnaCOM): a new method to create anatomo-functional maps from neuropsychological tests and structural MRI scan of subjects with brain lesions (2004) (2)
New lexicon and criteria for the diagnosis of Alzheimer's disease – Authors' reply (2011) (2)
The Mental and Cognitive Syndrome of Patients with Focal Lesions of Basal Ganglia (1996) (2)
Criteria for Prodromal Parkinson ’ s Disease (2015) (2)
Does surface dyslexia/dysgraphia relate to semantic deficits in the semantic variant of primary progressive aphasia? (2019) (2)
ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA (2014) (2)
[An anatomofunctional brain database]. (2002) (2)
[Markers of prodromal Alzheimer's disease]. (2012) (2)
COGEVIS: A New Scale to Evaluate Cognition in Patients with Visual Deficiency (2018) (2)
Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version (2007) (2)
[Neuropsychological evaluation can contribute to the diagnosis of movement disorders]. (2003) (2)
BRAAK NEUROFIBRILLARY STAGES, THAL AMYLOID PHASES, AND BRAIN WEIGHT: INFLUENCE OF LEWY PATHOLOGY AND CREUTZFELDT-JAKOB DISEASE (2014) (2)
Converting disease maps into heavyweight ontologies: general methodology and application to Alzheimer's disease. (2021) (2)
[Procedural learning and Parkinson disease: implication of striato-frontal loops]. (2001) (2)
Changing concepts and new definitions for Alzheimer’s disease (2016) (2)
Gantenerumab in‐depth outcomes (2020) (2)
Frontal Assessment Battery (2014) (2)
Frontal presentations of Alzheimer's disease: A series of people with biological evidence by CSF biomarkers (2013) (2)
Aptamarker prediction of brain amyloid-β status in cognitively normal individuals at risk for Alzheimer's disease. (2021) (2)
NOVEL ALZHEIMER’S DISEASE BIOMARKER-GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: Aβ1-42, TOTAL-TAU, PHOSPHORYLATED-TAU, NFL, NEUROGRANIN, AND YKL-40 (2018) (1)
[Parkinsonian syndromes. Etiology, diagnosis, treatment]. (1993) (1)
Ask The Experts: New diagnostic criteria for Alzheimer’s disease (2012) (1)
Demence semantique associeeaune sclerose laterale amyotrophique Semantic dementia associated with amyotrophic lateral sclerosis (2009) (1)
No effect of the alpha1-antichymotrypsin A allele in Alzheimer's disease. (1997) (1)
[Update on Alzheimer's disease]. (2009) (1)
THE INSIGHT COHORT: BASELINE ANALYSIS OF STRUCTURAL MR IMAGING IN ASYMPTOMATIC SUBJECTS AT RISK FOR ALZHEIMER'S DISEASE (2016) (1)
Solanezumab in‐depth outcomes (2020) (1)
Alzheimer’s disease brain atrophy subtypes are associated with incident dementia in subjective cognitive complaint and mild cognitive impairment (2020) (1)
Biomarker counseling, disclosure of diagnosis, and follow‐up in patients with mild cognitive impairment: A European survey of EADC centers (2020) (1)
Alzheimer's: Are we winning the fight? Not so sure. (2020) (1)
DIAGNOSTIC VALUE OF THE AMNESTIC SYNDROME FOR ALZHEIMER’S DISEASE: A CLINICOPATHOLOGICAL STUDY (2019) (1)
Confusion, dementia andanticholinergics inParkinson's disease (1982) (1)
VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION (2014) (1)
Reduced regional cortical thickness rate of change in donepezil-treated subjects with suspected prodromal Alzheimer’s disease: A longitudinal, multi-centric, double-blind, randomized, placebo-controlled trial (2015) (1)
THE FEASIBILITY OF AN INTERNET-BASED SUPPORT PROGRAM FOR INFORMAL CAREGIVERS OF ADULTS WITH EARLY-ONSET DEMENTIA: A MULTI-CENTRE RCT STUDY IN ENGLAND, FRANCE AND GERMANY (2017) (1)
Mutations in the neuroserpin gene are rare in familial dementia (2000) (1)
[THE SFN INTERNATIONAL MEETING Alzheimer's disease and dementia]. (2006) (1)
784 Genetic studies of Alzheimer's disease in 434 French families (1996) (1)
Cultural diversity and the measurement of functional impairment: A cross-cultural validation of the Amsterdam IADL Questionnaire (2019) (1)
Early cognitive, structural and microstructural changes in c9orf72 presymptomatic carriers before 40 years of age (2018) (1)
The effects of apomorphine on attentional processing in Parkinson's disease. (1999) (1)
Unravelling the impact of frontal lobe impairment for social dysfunction in myotonic dystrophy type 1 (2022) (1)
Correlation between brain atrophy in MRI and CSF markers in Alzheimer's disease (AD) (2010) (1)
ARGO trial (2012) (1)
Two-year results of the REGAIN study, a placebo-controlled trial with the non-ergot dopamine agonist piribedil as early treatment of Parkinson's disease (PD) (2005) (1)
EFFECT OF CHOLINESTERASE INHIBITORS ON BRAIN CHOLINERGIC STRUCTURES (2017) (1)
Paris: A new comprehensive language tool for the diagnosis and categorization of primary progressive aphasia (2015) (1)
No e V ect of the á 1-antichymotrypsin A allele in Alzheimer ’ s disease (1998) (1)
Impact of the New Conceptual Framework of Alzheimer’s Disease in Imaging Studies (2020) (1)
Logopenic Variant of Primary Progressive Aphasia in Lewy Body Dementia: Beyond Alzheimer's Disease (P05.038) (2012) (1)
[Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease]. (1996) (1)
Brain network for spatial awareness Evidence from diffusion tensor tractography. (2008) (1)
[Study methods of drugs in Alzheimer disease]. (1996) (1)
Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. (2017) (1)
[A new conception of Alzheimer disease]. (2008) (1)
Recommendations for the diagnosis and treatment of Alzheimer's disease and other disorders associated with dementia: The EFNS guidelines (2008) (1)
Dopaminergic modulation of cognition in Parkinson's disease: the effects of apomorphine (1998) (1)
Anatomy and Disorders of Frontal Lobe Functions: Fundamental Functions (2020) (1)
[Subjective cognitive complaint. From anxiety to prodromal Alzheimer's disease?]. (2013) (1)
INSIGHT-AD STUDY: A MONOCENTRIC COHORT FOR THE STUDY OF THE PRECLINICAL STAGE OF ALZHEIMER'S DISEASE (2016) (1)
Markers of prodromal Alzheimer's disease in the clinic (2010) (1)
ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN PROTEIN WITH BRAIN AMYLOID STATUS IN A PRECLINICAL COHORT OF SUBJECTIVE MEMORY COMPLAINERS: THE INSIGHT-PREAD STUDY (2017) (1)
PLASMA BETA-SECRETASE 1 CONCENTRATIONS IMPACT PLASMA NFL CONCENTRATIONS IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR AD: CROSS-SECTIONAL AND LONGITUDINAL STUDIES (2019) (0)
BIOMARKER-GUIDED STRATIFICATION APPROACH OF THE CLINICAL CONTINUUM OF ALZHEIMER’S DISEASE USING UNSUPERVISED CLUSTERING METHODS (2019) (0)
REDUCED WHITE MATTER INTEGRITY OF THE ROSTRAL LIMBIC SYSTEM PATHWAYS IN HEALTHY ELDERLY APOE E4 ALLELE CARRIERS (2016) (0)
[Dementia: new concepts, new goals]. (2013) (0)
Frequency and Phenotypes Associated with C9ORF72 Repeat Expansion in French FTLD and FTLD-ALS Patients (S54.003) (2012) (0)
SHORT-TERM PREDICTION OF CONVERSION FROM MILD COGNITIVE IMPAIRMENT TO DEMENTIA IN PATIENTS IN THE MEMENTO COHORT, 2011-2016 (2017) (0)
Impact of the IWG/Dubois Criteria for Alzheimer’s Disease in Imaging Studies (2014) (0)
Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer ’ s disease from cortical dementias (2016) (0)
TWO-LEVEL DIAGNOSTIC CLASSIFICATION USING CEREBROSPINAL FLUID NEUROGRANIN IN ALZHEIMER'S DISEASE (2017) (0)
[Letter on the editorial by Gilles Chopart et al. "early diagnosis of Alzheimer's disease: are we too close to the tree to see the forest?"]. (2014) (0)
Using DMAE for the treatment of mild cognitive impairment (2006) (0)
Address from the President, February 2018 (2018) (0)
P1-335: The neuronal substrate of amnestic syndrome in Alzheimer's disease: A VBM and volumetric MRI study (2008) (0)
ALZHEIMER'S DISEASE DETECTION AT THE PRECLINICAL STAGE USING A NOVEL SNP GENOTYPING ARRAY (2016) (0)
PRECLINICAL ALZHEIMER’S DISEASE: WHICH EEG BIOMARKERS FOR PRECISION MEDICINE? (2019) (0)
Reduced awareness of cognitive decline is associated with brain amyloid load in asymptomatic elderly individuals at risk for AD: A longitudinal study (2020) (0)
THE EVALUATION OF MTOR PATHWAY DYSREGULATION AS A NOVEL BLOOD-BASED PHENOTYPIC RISK BIOMARKER FOR THE ASSESSMENT OF ALZHEIMER'S DISEASE AND DEMENTIA (2014) (0)
How could potential selection bias impact the analysis of correlates of cerebrospinal fluid biomarkers? the memento cohort (2015) (0)
Reply: Brief cognitive tests in the screening of dementia in Parkinson's disease (2011) (0)
PLASMA BETA-SECRETASE 1 CONCENTRATIONS PREDICT GLOBAL AND REGIONAL BRAIN BURDEN OF AMYLOID-β IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR AD: CROSS-SECTIONAL AND LONGITUDINAL STUDIES (2019) (0)
Comparison of Movement Disorder Society Criteria for Parkinson's Disease Dementia with Routine Clinical Neuropsychological Testing (PD4.006) (2012) (0)
S.09.01 New concept and new criteria of Alzheimer's disease (2008) (0)
Executive functioning and not attribution of intention predicts environmentally-driven behaviours in behavioural-variant frontotemporal dementia (2016) (0)
Faculty of 1000 evaluation for Classification of primary progressive aphasia and its variants. (2011) (0)
THE NEURONAL COMPENSATION MODEL OF THE PRECLINICAL STAGE OF ALZHEIMER'S DISEASE: RESULTS FROM THE INSIGHT-PRE AD STUDY (2018) (0)
[Consensus statement on severe dementia]. (2005) (0)
Faculty Opinions recommendation of A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. (2011) (0)
VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION (2014) (0)
Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers (2020) (0)
biomarkers DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and (2007) (0)
Current status and quantitative results of the AMYPAD prognostic and natural history study (2020) (0)
Metrifonateof its Use in Alzheimer's Disease (2000) (0)
degeneration: comparison with Parkinson's disease and progressive supranuclear palsy (0)
[The concept of frontotemporal lobar degeneration]. (2002) (0)
Naming in Primary Progressive Aphasia: The Contribution of the Temporal Lobe (P03.088) (2013) (0)
Sensitivity and specificity of EEG biomarkers of AD at the preclinical stage (2020) (0)
Amyloid deposition in early- and late-onset Alzheimer's disease: Two case reports using [11C]PIB-PET (2010) (0)
Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease (2018) (0)
BIOMARKERS SUGGESTACTIVATION OF INNATE IMMUNITY IN SUBCLINICAL CEREBROVASCULAR DISEASE (2018) (0)
Detection of prodromal Alzheimer's disease using whole-brain atlas-based classification (2009) (0)
N C ] 3 J an 2 01 7 Loss of inter-frequency brain hubs in Alzheimer ’ s disease (2017) (0)
APOE AFFECTS THE NETWORK ARCHITECTURE OF THE RESTING BRAIN IN INDIVIDUALS AT RISK FOR AD (2019) (0)
[For a new definition of the Alzheimer's disease]. (2012) (0)
DOES BRAIN AMYLOID DEPOSITION IMPACT EVERYDAY FUNCTIONING IN SUBJECTS WITH COGNITIVE COMPLAINTS? RESULTS FROM THE INSIGHT COHORT (2017) (0)
Are cerebrospinal fluid levels of neurogranin associated with hippocampal atrophy and brain white matter volume decrease? (2015) (0)
Basic clinical knowledge (2008) (0)
Pathways involved in the relationship between resilience and cognitive function: The Memento cohort (2020) (0)
Concepts of Preclinical Dementias (2011) (0)
CLINICAL SIGNIFICANCE OF IN-VIVO STAGING OF REGIONAL AMYLOID DEPOSITION IN SUBJECTIVE MEMORY COMPLAINERS (2018) (0)
COGNITION AND LOW VISION: COGEVIS (2018) (0)
INNOVATIVE BIOMARKER-GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER’S DISEASE DEMENTIA (2018) (0)
P4-228: Nicotinic acetylcholine receptors (nAChRs) imaging with PET in Alzheimer's disease (2008) (0)
Predicting factors of cognitive progression in preclinical AD: A five‐year follow‐up of the insight‐study (2020) (0)
AWARENESS OF MEMORY DECLINE IN ASYMPTOMATIC AT RISK FOR ALZHEIMER’S DISEASE: THE META-MEMORY RATIO (2019) (0)
[Alzheimer's disease: a few pathophysiological data]. (1999) (0)
A specific pattern of memory errors in asymptomatic at‐risk for AD (2020) (0)
ASSOCIATION OF MULTIMORBIDITY WITH NEURODEGENERATION AND BRAIN AMYLOID LOAD IN COGNITIVELY NORMAL SUBJECTS (2017) (0)
EEG EVIDENCE OF COMPENSATORY MECHANISMS IN PRECLINICAL ALZHEIMER’S DISEASE (2019) (0)
Association of CSF α-synuclein and tau protein concentrations with amyloid mean cortical standard uptake value ratios in preclinical subjective memory complainers stratified by Alzheimer’s disease biomarkers: the INSIGHT-preAD study (2018) (0)
Depression, anxiety and level of memory complaint promote memory clinic help-seeking for subjective cognitive decline (2016) (0)
Neuropsychologic Features of Parkinson's Dementias (2011) (0)
IS THE PROSPECTIVE ASSOCIATION BETWEEN DOMAIN-SPECIFIC COGNITIVE IMPAIRMENT AND INCIDENT DEMENTIA MODIFIED BY EDUCATION? THE MEMENTO COHORT (2017) (0)
SPONTANEOUS LOW-FREQUENCY BOLD SIGNAL FLUCTUATIONS IN OLDER SUBJECTIVE MEMORY COMPLAINERS WITH OR WITHOUT BRAIN AMYLOIDOSIS: THE INSIGHT-PRE-AD STUDY (2017) (0)
IN COGNITIVELY NORMAL INDIVIDUALS, THE BEST CONCORDANCE BETWEEN CSF BIOMARKERS AND PET AMYLOID IS OBSERVED WITH THE COMBINATION OF B-AMYLOID1-42 AND PHOSPHORYLATED TAU (2017) (0)
15 Validation and implementation of the new diagnostic criteria for Alzheimer's disease (2012) (0)
Aging and sex impact plasma NFL and t‐Tau trajectories in individuals at risk for Alzheimer’s disease (2020) (0)
II.2 Parkinson's disease dementia and Lewy body dementia (2006) (0)
Harmonization and innovation of cognitive, behavioural and functional assessment in neurodegenerative dementias (2015) (0)
lncRNAs as a novel source of diagnostic applications for early Alzheimer’s disease and other dementia types (2020) (0)
Neurofeedback as a neurorehabilitation tool for memory deficits : a phase 0 clinical trial (2017) (0)
The concept of the new criteria: “Opening the window” (2009) (0)
CORTICAL SULCI WIDTH AND INCIDENT DEMENTIA IN OUTPATIENTS ATTENDING FRENCH MEMORY CLINICS: THE MEMENTO COHORT (2018) (0)
ARE ALZHEIMER’S DISEASE RISK GENES RELATED TO MARKERS OF BRAIN PATHOLOGY? THE MEMENTO COHORT (2016) (0)
Evaluation of the effect of transcranial direct current stimulation on language impairments in the behavioural variant of frontotemporal dementia (2022) (0)
Cross-cultural differences in instrumental activities of daily living (IADL): Translations and adaptations of the amsterdam iadl questionnaire (2015) (0)
Cerebral Autosomal Dominant Arteriopathy withSubcortical Infarcts andLeukoencephalopathy, Genetic Homogeneity, andMapping of theLocuswithin a 2-cMInterval (1996) (0)
THE BIOMARKER-BASED DIAGNOSIS OF ALZHEIMER’S DISEASE: LESSONS FROM ONCOLOGY (2016) (0)
New Results - Segmentation of the hippocampus in neurodegenerative dementias (2013) (0)
Résultats d’efficacité, de tolérance et des biomarqueurs de SCarlet RoAD—une étude de phase 3 internationale du gantenerumab chez des patients atteints d’une maladie d’Alzheimer (MA) à la phase prodromale (2016) (0)
[For a "neurocognitive" approach to memory: value of neuropsychology]. (1998) (0)
P2-197: Progressive prosopagnosia and fluent aphasia preceding the appearance of amyotrophic lateral sclerosis (2008) (0)
MORAL EMOTIONS IN FRONTOTEMPORAL DEMENTIA (2019) (0)
Pet study of brain serotonergic 5 ht 2 receptors in alzheimer type dementia atd (1991) (0)
FUNCTIONAL EEG BIOMARKER BATTERY FOR EARLY-STAGE PREDICTION OF ALZHEIMER'S DISEASE IN ASYMPTOMATIC, AT-RISK, AMYLOID-POSITIVE ELDERLY INDIVIDUALS (2014) (0)
Brief communication CSF tau markers are correlated with hippocampal volume in Alzheimer's disease (2011) (0)
O1-05-06 Free and Cued Recall Test in memory clinics: A good predictor of conversion to AD or a marker of prodromal AD ? (2006) (0)
[Role of clinical trials in memory clinics]. (1997) (0)
COGnitive Evaluation in VISual Impairment Scale (2019) (0)
CATI: A Large Distributed Infrastructure for the Neuroimaging of Cohorts (2016) (0)
O3-06-04 MRI atrophy at baseline in Alzheimer’s disease differentiates fast and slow decliners better than neuropsychology: A 3-year longitudinal study (2006) (0)
CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOID-PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS (2018) (0)
THE MORAL EMOTIONS ASSESSMENT: A NEW TOOL FOR THE EARLY DIAGNOSIS OF FRONTOTEMPORAL DEMENTIA (2016) (0)
LONGITUDINAL EFFECT OF BIOLOGICAL VARIABLES ON PLASMA NFL AND T-TAU CONCENTRATIONS ON SUBJECTIVE MEMORY COMPLAINERS (INSIGHT-PREAD-COHORT): A 3-YEAR FOLLOW-UP STUDY (2019) (0)
New version of the UPDRS (MDS-UPDRS): Factor analysis (2008) (0)
DEVELOPMENT OF A CONSENSUS ROADMAP TO HARMONIZE COGNITIVE ASSESSMENT (2019) (0)
Short report Confusion , dementia and anticholinergics in Parkinson ' s disease (0)
[Dopaminergic agonists in Parkinson disease]. (1986) (0)
THE MEMORY BINDING TEST (MBT) IN SUBJECTS WITH SUBJECTIVE MEMORY DECLINE (SMD) (2016) (0)
Enlightening behavioral disturbances in myotonic dystrophy type 1 through neuropsychology and imaging correlations: Insights from the frontal and temporal lobe functions (2020) (0)
An Ecological Approach of a Dysexecutive Syndrome (2002) (0)
The eating behavior inventory (EBI): A new clinical tool for the diagnosis of frontotemporal dementia (2015) (0)
COMBINED ADDED VALUE OF CEREBROSPINAL FLUID NEUROGRANIN AND NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE DIAGNOSIS AND CLASSIFICATION OF PRODROMAL AND ALZHEIMER’S DISEASE DEMENTIA (2016) (0)
ADDIA, A MULTICENTER CLINICAL STUDY OF PROOF-OF-PERFORMANCE TO VALIDATE BLOOD-BASED BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE (AD): THE STUDY PROTOCOL (2018) (0)
PLASMA BIOMARKER PROFILE OF AMYLOID, TAU, AND NEURONAL PATHOPHYSIOLOGY IN COGNITIVELY NORMAL PRECLINICAL INDIVIDUALS STRATIFIED BY AMYLOID-PET STATUS (2016) (0)
INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL (2018) (0)
Case Studies in Dementia: Subjective cognitive complaint (2011) (0)
Multimodal screening for neurodegeneration in preclinical Alzheimer’s disease using EEG, APOE4 genotype, neuropsychological and MRI data (2020) (0)
DIFFERENT SEX VULNERABILITY OF THE BASAL FOREBRAIN CHOLINERGIC SYSTEM IN RELATION WITH IN VIVO BRAIN AMYLOID LOAD (2019) (0)
Featured Article CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study (2015) (0)
DEFICITS IN VISUAL RECOGNITION MEMORY: A MARKER OF EARLY MESIAL TEMPORAL LOBE DEGENERATION IN NONDEMENTED OUTPATIENTS FROM MEMORY CLINICS? (2016) (0)
Modi fi cations of the endosomal compartment in peripheral blood mononuclear cells and fi broblasts from Alzheimer ’ s disease patients (2016) (0)
COMPARATIVE LONGITUDINAL CHANGE OF FUNCTIONAL CONNECTIVITY, DIFFUSION AND STRUCTURAL MRI MARKERS IN A PRODROMAL/MILD ALZHEIMER’S DISEASE POPULATION (2016) (0)
[Alzheimer disease and immunotherapy: hope or disillusion?]. (2006) (0)
Age differences in the association of white matter lesions with the occurrence of dementia: The memento cohort (2015) (0)
Are subjects with preclinical AD the best population for the study of disease modifiers treatment? (2016) (0)
P2-198: Short-term memory deficit related to progressive biparietal atrophy: A Ganser-like symptom (2008) (0)
SEXUAL DIMORPHISM IN PLASMA BETA-SECRETASE 1 CONCENTRATIONS IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR AD: CROSS-SECTIONAL AND LONGITUDINAL STUDIES (2019) (0)
P1.030 Detection of Parkinson's disease dementia in routine practice (2009) (0)
Key symposium: updating Alzheimer's disease diagnosis ‐ implications for prevention and treatment (2014) (0)
Biomarker Based Diagnosis Of Very Mild Alzheimer'S Disease: A Multicenter Study (2009) (0)
Selection of amyloid positive pre-symptomatic subjects using automatic analysis of neuropsychological and MRI data for cost effective inclusion procedures in clinical trials (2017) (0)
APOE GENE MODIFIES THE LINK BETWEEN TYPE 2 DIABETES AND DEMENTIA RISK: THE MEMENTO COHORT (2016) (0)
Neural correlates of the mini-SEA (Social cognition and Emotional Assessment) in behavioral variant frontotemporal dementia (2013) (0)
ASSOCIATION OF CSF ALPHA-SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER’S DISEASE BIOMARKERS (2018) (0)
Frontotemporal dementia (1999) (0)
DELAYED REACTION STUDY IN PATIENTS WITH SCHIZOPHRENIA (1992) (0)
REDUCED BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO MEN (2018) (0)
USEFULNESS OF THE PET-PIB IMAGING FOR THE DIAGNOSIS OF AD IN DAILY CLINICAL PRACTICE (2014) (0)
AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PRE-AD COHORT (2018) (0)
Role of the prefrontal cortex in sequential processing of actions and words (1997) (0)
P-071 Description of a memory self-evaluation scale (McNair and Kahn scale) in the 2854 included patients of GuidAge prevention study (2007) (0)
1.206 UPDATE IN THE CLINICAL PRESENTATION AND NATURAL HISTORY OF DCB AND PSP PATIENTS (2012) (0)
Donepezil decreases rate of hippocampal atrophy in patients with prodromal Alzheimer's disease (2011) (0)
[Central dopaminergic deficiency and cognitive disorders in man]. (1989) (0)
DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKER-GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER’S DISEASE (2017) (0)
P2-353 Automated volumetry of the amygdala and the hippocampus in Alzheimer’s disease (2006) (0)
A New Concept and New Criteria for Alzheimer's Disease (2007) (0)
EEG: A valuable tool to screen for neurodegeneration in preclinical Alzheimer’s disease (2020) (0)
Asymptomatic individuals at risk for alzheimer's disease: who are they and what can we do with them? (2014) (0)
In‐vivo characterization of progressive amnestic syndrome due to suspected neurodegenerative non‐Alzheimer’s disease (2020) (0)
ASSOCIATION BETWEEN BRAIN NETWORK DYNAMICS AND PLASMA BIOMARKERS IN COGNITIVELY INTACT INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASE (2019) (0)
DIAGNOSIS VALUE OF HIPPOCAMPAL VOLUME IN BIOLOGICALLY CONFIRMED AD (2014) (0)
INCREASED RESILIENCE TO ALZHEIMER’S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN (2018) (0)
C.05.03 Emerging new strategies for early AD diagnosis (2008) (0)
Hysteria or Dementia? A Case of Atypical Clinical Onset of Frontotemporal Dementia Associated with a Progranulin Mutation (2019) (0)
Ratio P-Tau/Ab42 discriminates Alzheimer’s disease from semantic dementia and frontotemporal dementia with high specificity (2009) (0)
[Toward a preventive management Alzheimer's disease]. (2020) (0)
CEREBROSPINAL FLUID BIOMARKER PROFILE OF AMYLOID, TAU, SYNAPTIC, MICROGLIAL, AND LYSOSOMAL PATHOPHYSIOLOGY IN COGNITIVELY NORMAL PRECLINICAL INDIVIDUALS STRATIFIED BY AMYLOID-PET STATUS (2016) (0)
EVIDENCE FOR COGNITIVE COMPENSATION IN EARLY AMYLOIDOSIS IN HIGH-PERFORMING HEALTHY ELDERLY AT RISK FOR ALZHEIMER'S DISEASE (2018) (0)
[Dysexecutive syndromes and degenerative diseases]. (2004) (0)
PREVALENCE AND CHARACTERISTICS OF PATIENTS WITH ALZHEIMER’S DISEASE ELIGIBLE FOR A DISEASE MODIFYING DRUG (PANACEA) (2016) (0)
CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS (2018) (0)
Validation of the amnestic syndrome of the hippocampal type in Alzheimer's disease using CSF biomarkers and PiB-PET (2012) (0)
ANALYSIS OF EARLY ENDOSOMES IN PERIPHERAL BLOOD MONONUCLEAR CELLS IN ALZHEIMER'S DISEASE PATIENTS (2014) (0)
ASSOCIATION BETWEEN MULTIPLE NEUROIMAGING MARKERS AND COGNITIVE PROFILES IN THE MEMENTO COHORT (2014) (0)
Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimer’s disease (2020) (0)
Cognitive Tests in the Screening of Dementia in Parkinson ’ s Disease (2011) (0)
Resting State Functional Connectivity in Posterior Cortical Atrophy (P03.086) (2012) (0)
Faculty Opinions recommendation of Ecology of the aging human brain. (2011) (0)
REDUCED BASAL FOREBRAIN ATROPHY PROGRESSION IN DONEPEZIL-TREATED PRODROMAL ALZHEIMER'S DISEASE PATIENTS (2017) (0)
DIFFERENT STRUCTURAL CONNECTIVITY PATTERNS IN MILD COGNITIVE IMPAIRMENT STRATIFIED BY AMYLOID AND NEURODEGENERATION BIOMARKERS (2017) (0)
Multi-dimensional profiling of elderly at-risk for Alzheimer's disease in a differential framework (2019) (0)
COMPARISON OF BRAIN MORPHOLOGY BETWEEN TWO DATABASES OF ELDERLY COGNITIVELY INTACT INDIVIDUALS FOR THE VALIDATION OF HIPPOCAMPAL VOLUME NORMATIVE DATA IN THE FRENCH INSIGHT-PRE AD COHORT (2017) (0)
shown with MRI . disease : the role of hippocampal atrophy as Memory disorders in probable Alzheimer ' s and (0)
Association between subjective cognitive decline and Young's early maladaptive schemas (2016) (0)
Genetics of early-onset Alzheimer disease in France (2011) (0)
Communicating the diagnosis of Alzheimer's disease: Dilemmas and perspectives (2014) (0)
CONCURRENT EEG/FMRI NETWORK DYNAMICS ALTERATIONS IN COGNITIVELY INTACT INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASE (2019) (0)
[Not Available]. (2010) (0)
The Impact of Interlocutor Repeats on the Discourse of Patients with Frontal Lobe Damages (2006) (0)
Gantnerumab In-depth Outcomes (2020) (0)
[Dementia and memory: morphologic imagery with MRI]. (1998) (0)
European-Huntington-Disease-Initiative (EHDI)-Study: Effect of riluzole on disease progression (2005) (0)
Correlation between medial temporal lobe atrophy in MRI and CSF markers in Alzheimer's disease (AD) (2009) (0)
AGREEMENT, SENSITIVITY, AND SPECIFICITY BETWEEN THE NEUROPATHOLOGICAL AND CLINICAL DIAGNOSES OF ALZHEIMER'S DISEASE (AD) DEMENTIA: A MULTICENTER LONGITUDINAL STUDY (2014) (0)
Caudate nucleus involvement in the early stages of cognitive procedural learning (2000) (0)
Anatomy and Disorders of Frontal Lobe Functions: Higher-Order Functions (2020) (0)
Role of the prefrontal cortex in sequential processing of actions and words: A 3T fMRI study (1997) (0)
Review Article Mechanical stress models of Alzheimer's disease pathology (2016) (0)
Last and art aphasia screening tools: Switching context from stroke to neurodegenerative diseases (2015) (0)
UNBIASED BIOMARKER-BASED CATEGORIZATION OF A MULTICENTER COHORT OF ADD, MCI AND FTD PATIENTS (2017) (0)
THE MINI EATING BEHAVIOR INVENTORY (MINI EBI): A 10-ITEM CLINICAL TOOL FOR THE EARLY DIAGNOSIS OF FRONTOTEMPORAL DEMENTIA (2017) (0)
Long-Term Retention Deficit Involvement in Prodromal Alzheimer’s Disease (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Bruno Dubois?

Bruno Dubois is affiliated with the following schools:

Sorbonne University